Cover

The potential of next-generation platforms in transforming patient recruitment.

Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.

Multiple Phase III trials and open label extensions show Bimzelx (bimekizumab-bkzx) offers an effective approach in targeting key inflammatory pathways involved in psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.

What learning science has taught us about the drivers and predictors of change—and applying those to clinical research practice.

Phase III DREAMM-7 trial data show that the combination of Blenrep (belantamab mafodotin) with bortezomib and dexamethasone (BorDex) significantly improved overall survival in patients with relapsed or refractory multiple myeloma compared to standard treatment with Darzalex (daratumumab) and BorDex.